BioVentrix Reports Successful First-in-Man Transcatheter Clinical Procedure With Revivent-TC™ System for Heart Failure Treatment

Published: Oct 01, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN RAMON, Calif. & VILNIUS, Lithuania--(BUSINESS WIRE)--BioVentrix, a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced the first-in-man use of its Revivent-TC™ Myocardial Anchoring System, via Less Invasive Ventricular Enhancement™ or the LIVE™ procedure. The successful procedure, used to reshape and reduce the left ventricle (LV), was performed on a 61-year-old man suffering from advanced HF in the interventional catheterization laboratory at Vilnius University Hospital in Vilnius, Lithuania. The procedure was performed by Dr. med. Gintaras Kalinauskas and Dr. med. Gierdrius Davidavicius, a cardiac surgery-cardiology physician team.

Help employers find you! Check out all the jobs and post your resume.

Back to news